Silence Therapeutics PLC Director/PDMR Shareholding (7226O)

TIDMSLN

RNS Number : 7226O

Silence Therapeutics PLC

03 October 2019

Director/PDMR Shareholding

October 3, 2019

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that on October 2(nd) 3,171 Shares were purchased by Alistair Gray, Non-Executive Director of the Company, at GBP1.89 per share.

Following this purchase, Alistair Gray is interested in 7,019 ordinary shares (0.01%) of the issued share capital of the Company and will be interested in 8,645 ordinary shares (0.01%) of the issued share capital of the Company following the admission of the new shares on October 7(th) pursuant to his exercise of Conditional Share Awards announced on October 1(st) .

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1.   Details of the person discharging managerial responsibilities 
       (PDMR) / person closely associated 
 a)   Name                         Alistair Gray 
     ---------------------------  -------------------------------------------- 
 2.   Reason for the notification 
     ------------------------------------------------------------------------- 
 a)   Position / status            Non-Executive Director 
     ---------------------------  -------------------------------------------- 
 b)   Initial notification         Initial notification 
       / Amendment 
     ---------------------------  -------------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------------- 
 a)   Name                         Silence Therapeutics plc 
     ---------------------------  -------------------------------------------- 
 b)   LEI                          213800SSURRJBX85SQ91 
     ---------------------------  -------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------------- 
 a)   Description of               Ordinary Shares of 5 pence each in Silence 
       the financial instrument,    Therapeutics plc 
       type of instrument 
 
       Identification 
       code                         ISIN for Silence Therapeutics plc Ordinary 
                                    Shares: 
                                    GB00B9GTXM62 
     ---------------------------  -------------------------------------------- 
 b)   Nature of the transaction    Purchase of Ordinary Shares in Silence 
                                    Therapeutics plc 
     ---------------------------  -------------------------------------------- 
 c)   Prices(a) and volume(s)        Price      Volume 
                                      GBP1.89    3,171 
                                                ------- 
     ---------------------------  -------------------------------------------- 
 d)   Aggregated information 
       - Aggregated volume           3,171 Ordinary Shares 
       - Price                       GBP5,993.19 
     ---------------------------  -------------------------------------------- 
 e)   Date of the transaction      02 October 2019 
     ---------------------------  -------------------------------------------- 
 f)   Place of the transaction     London Stock Exchange, AIM 
     ---------------------------  -------------------------------------------- 
 

Enquiries:

 
 Silence Therapeutics plc                          Tel: [phone] 
  Dr David Horn Solomon, Chief Executive Officer    6900 
 Peel Hunt LLP (Nominated Adviser and Broker)      Tel: [phone] 
  James Steel/Oliver Jackson                        8900 
 European IR                                       Tel: +44 (0) 20 
  Consilium Strategic Communications                3709 5700 
  Mary-Jane Elliott/Chris Welsh/Angela Gray 
  [e-mail] 
 US IR                                              Tel: [phone] 
  Westwicke Partners 
  Peter Vozzo 
  [e-mail] 
 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHBSBDGRXGBGCX

(END) Dow Jones Newswires

October 03, 2019 10:40 ET (14:40 GMT)